Oklahoma is currently home to 936 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Oklahoma City, Tulsa, Norman and Edmond. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
Recruiting
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design. The study will evaluate the safety and pharmaco... Read More
Gender:
All
Ages:
Between 18 years and 49 years
Trial Updated:
03/07/2023
Locations: Research Site, Oklahoma City, Oklahoma
Conditions: Cystic Fibrosis
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2023
Locations: Local Institute, Tulsa, Oklahoma
Conditions: Multiple Myeloma
A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer
Recruiting
This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single arm) includes participants with recurrent ovarian cancer. Cohort B will not be initiated. Cohort C (randomized-2 arms) includes participants with newly diagnosed ovarian cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/09/2023
Locations: GSK Investigational Site, Oklahoma City, Oklahoma
Conditions: Ovarian Neoplasms
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
Recruiting
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
Gender:
All
Ages:
Between 0 days and 17 years
Trial Updated:
02/06/2023
Locations: OU Medical Center Investigational Drug Pharmacy, Oklahoma City, Oklahoma
Conditions: Venous Thromboembolism
Stress Hydrocortisone In Pediatric Septic Shock
Recruiting
SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the proportion of children with poor outcomes, defined as death or severely impaired health-related quality of life (HRQL), as assessed at 28 days follo... Read More
Gender:
All
Ages:
Between 1 month and 17 years
Trial Updated:
02/02/2023
Locations: The Children's Hospital at Oklahoma University Medical Center, Oklahoma City, Oklahoma
Conditions: Septic Shock
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
Recruiting
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
Gender:
All
Ages:
20 years and below
Trial Updated:
01/30/2023
Locations: The University of Oklahoma, Oklahoma City, Oklahoma
Conditions: Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
Smoking, Stress, and Mobile Technology
Recruiting
We seek to refine and evaluate the novel mobile intervention, Mobile Anxiety Sensitivity Program for Smoking (MASP) which was initially developed and previously tested by our team, targeting sensitivity to interoceptive stress, and to apply it among African American smokers. Our culturally adapted intervention is framed within a sociocultural context of interoceptive stress, which is supported by theory, empirical evidence, and characteristics of African American smokers. The MASP app contains e... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2023
Locations: TSET Health Promotion Research Center, Oklahoma City, Oklahoma
Conditions: Smoking, Tobacco
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Recruiting
This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/13/2023
Locations: INTEGRIS Baptist Medical Center, Inc., Oklahoma City, Oklahoma
Conditions: Pulmonary Arterial Hypertension
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
Recruiting
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2023
Locations: University of Oklahoma, Oklahoma City, Oklahoma
Conditions: Multiple Myeloma
Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy
Recruiting
In previous studies, Proton Beam Radiation Therapy (PBRT) has been found to show better results in treating patients with cancer, both because there is better control of where in the body the radiation is directed and because it is associated with less severe long term side effects. However, there is limited published data demonstrating these results. The goal of the Proton and Photon Consortium Registry (PPCR) is to enroll children treated with radiation in order to describe the population that... Read More
Gender:
All
Ages:
21 years and below
Trial Updated:
01/05/2023
Locations: ProCure Proton Therapy Center- Oklahoma, Oklahoma City, Oklahoma
Conditions: Pediatric Patients Treated With Radiation Therapy
Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
Recruiting
Apheleia-001 is a prescreener that aims to identify and characterize participants with reported cognitive impairment using demographic information, clinical history, brief cognitive assessments, and blood-based biomarkers to distinguish appropriate participants for referral to a therapeutic AD clinical trial.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
12/28/2022
Locations: IPS Research, Oklahoma City, Oklahoma
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
Recruiting
A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types: Triple negative breast cancer Epithelial ovarian cancer Non-small cell lung cancer Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma Small cell lung can... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/29/2022
Locations: The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Gastric Adenocarcinoma, Breast Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Epithelial Ovarian Cancer, Gastroesophageal Junction Adenocarcinoma, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma